bluebird bio (NASDAQ:BLUE) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of bluebird bio (NASDAQ:BLUE - Free Report) in a research note issued to investors on Sunday morning. The firm issued a sell rating on the biotechnology company's stock.

A number of other research analysts have also recently commented on the company. Cantor Fitzgerald reaffirmed a "neutral" rating on shares of bluebird bio in a research report on Monday, September 16th. Wells Fargo & Company lowered their price target on shares of bluebird bio from $3.00 to $2.00 and set an "equal weight" rating on the stock in a research report on Wednesday, September 25th. JPMorgan Chase & Co. downgraded shares of bluebird bio from an "overweight" rating to a "neutral" rating in a report on Thursday, August 15th. Barclays reduced their price target on bluebird bio from $8.00 to $4.00 and set an "overweight" rating for the company in a research report on Thursday, August 15th. Finally, Royal Bank of Canada restated a "sector perform" rating and issued a $4.00 target price on shares of bluebird bio in a research note on Thursday, August 15th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $3.59.

bluebird bio Stock Performance

Shares of NASDAQ:BLUE traded up $0.02 during midday trading on Friday, reaching $0.41. The company had a trading volume of 5,976,533 shares, compared to its average volume of 3,923,621. bluebird bio has a 52-week low of $0.34 and a 52-week high of $5.53. The company's 50 day moving average price is $0.50 and its 200 day moving average price is $0.80. The company has a current ratio of 0.68, a quick ratio of 0.57 and a debt-to-equity ratio of 0.37. The stock has a market cap of $78.67 million, a P/E ratio of -0.18 and a beta of 0.76.

bluebird bio (NASDAQ:BLUE - Get Free Report) last issued its quarterly earnings results on Friday, September 13th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter. bluebird bio had a negative return on equity of 207.25% and a negative net margin of 567.29%. The company had revenue of $18.57 million for the quarter. As a group, sell-side analysts anticipate that bluebird bio will post -1.41 EPS for the current fiscal year.

Institutional Investors Weigh In On bluebird bio

A number of institutional investors have recently made changes to their positions in BLUE. Allegheny Financial Group LTD bought a new position in shares of bluebird bio in the second quarter worth approximately $25,000. Bayesian Capital Management LP purchased a new stake in shares of bluebird bio during the first quarter worth about $52,000. SG Americas Securities LLC grew its stake in shares of bluebird bio by 152.4% in the third quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company's stock worth $64,000 after purchasing an additional 74,185 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in bluebird bio by 113.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 54,714 shares of the biotechnology company's stock valued at $71,000 after purchasing an additional 29,113 shares during the period. Finally, American International Group Inc. raised its position in bluebird bio by 77.4% during the 1st quarter. American International Group Inc. now owns 94,371 shares of the biotechnology company's stock valued at $121,000 after purchasing an additional 41,177 shares during the last quarter. Hedge funds and other institutional investors own 87.43% of the company's stock.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.